UPS stock (NYSE:UPS) has surged 8% in a week after Citigroup's upgrade to a buy rating with a price target of $126. The company announced better-than-expected Q3 2025 results last October, and positive momentum from FedEx's solid performance has enhanced sentiment throughout the transportation sector.
TLT: 2026 Risk Factors To Consider As Shorts Pile In — Positive
TLT Seeking Alpha — January 09, 2026I view iShares 20+ Year Treasury Bond ETF as a hold, given balanced risk-reward and heightened uncertainty in 2026. Despite three Fed rate cuts in 2025, TLT's price action has been muted, signaling diminished safe-haven demand. Record U.S. debt and persistent inflation challenge the traditional 'flight to quality' thesis for TLT in recessions.
Options Corner: GEV Shrugs Off Downgrade Amid META, OKLO & VST Deal — Neutral
META OKLO GEV VST Schwab Network — January 09, 2026GE Vernova (GEV) appeared to shrug off a downgrade from Baird in the hour before Friday's opening bell. The downgrade comes After Meta Platforms (META) tapped Vistra (VST) and Oklo Inc. (OKLO) to supply electricity for the social media conglomerate.
HELE Q3 Earnings Meet Estimates, Home & Outdoor Sales Decline Y/Y — Negative
HELE Zacks Investment Research — January 09, 2026HELE's third-quarter earnings meet estimates as sales decline year over year, with Home & Outdoor weakness partly offset by Olive & June growth.
Salesforce Plunges 20% in a Year: Is CRM Stock Still a Hold? — Neutral
CRM Zacks Investment Research — January 09, 2026CRM shares are down 18% in a year, but AI momentum, enterprise expansion and discounted valuation suggest Salesforce may still be worth holding.
Amazon Pharmacy Expands Access to New Wegovy® Pill with Insurance and Cash-Pay Options — Neutral
AMZN Business Wire — January 09, 2026SEATTLE--(BUSINESS WIRE)--Amazon Pharmacy now offers Novo Nordisk's newly FDA-approved oral GLP-1 with transparent pricing and fast, free home delivery.
ENvue Medical Launches Program to Address Patient Pain and Discomfort with Indwelling Nasogastric Tubes Based on Previously Published, Peer-Reviewed Clinical Research — Neutral
FEED NAOV GlobeNewsWire — January 09, 2026The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes The program will integrate the Company's clinically validated NanoVibronix technology to improve comfort associated with indwelling nasogastric tubes
Service Corporation Revenue Mix: What's Powering the Top Line? — Positive
SCI Zacks Investment Research — January 09, 2026SCI's Q3 revenue rose 4.4% as cemetery preneed gains outweighed mixed funeral trends, reshaping the company's top-line mix.
SHEL Expects Higher Output in Q4 Despite Lower Oil Trading Performance — Neutral
SHEL Zacks Investment Research — January 09, 2026Shell estimates higher Q4 2025 oil and gas output, but warns oil trading will be significantly weaker as crude prices slide.
Broadcom experienced a decline of -17% over the past month. You might feel inclined to purchase more shares or perhaps consider decreasing your investment.
Telecom and Data Systems is now a focused fiber and tower platform post-US Cellular sale, with a clean balance sheet and disciplined capital allocation. TDS Telecom is accelerating fiber builds in underserved Tier-2/3 markets and leveraging FCC E-ACAM subsidies to convert rural copper to high-penetration fiber. Array Digital is transforming into a standalone tower business, with tenancy and margin expansion, and $1.8B in special dividends imminent from spectrum monetization.
Amazon: The Window To Buy At 10-Year Lows Is Slamming Shut — Neutral
AMZN Seeking Alpha — January 09, 2026Amazon.com, Inc. is rated a Strong Buy for 2026+, driven by low valuations and robust growth in AWS and emerging tech initiatives. AMZN trades at a 10-year low P/E multiple, despite accelerating AWS growth and minimal reliance on its retail segment for future upside. Key growth drivers include AWS, Project Kuiper (LEO satellites), agentic AI, custom silicon, and the Prime ecosystem, positioning AMZN against competitors like Starlink.
Silicone Laboratories Senior VP Sells Thousands of Shares Towards End of 2025 — Neutral
SLAB The Motley Fool — January 09, 2026A Silicon Laboratories insider exerised multiple options and sold over 6,000 shares in December 2025 through open-market transactions. This exercise-and-sale event follows a pattern of administrative trades, reflecting a 23.46% ownership reduction since May 2024.
Freeport-McMoRan Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before January 12, 2026 to Discuss Your Rights - FCX — Neutral
FCX PRNewsWire — January 09, 2026NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Freeport-McMoRan Inc. ("Freeport-McMoRan Inc." or the "Company") (NYSE: FCX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Freeport-McMoRan Inc. investors who were adversely affected by alleged securities fraud between February 15, 2022 and September 24, 2025.
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) — Neutral
BLK GlobeNewsWire — January 09, 2026ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS9 January 2026 at 16:00 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 8 January 2026 below five (5) per cent of Orion Corporation's total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total …
Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026 — Neutral
AKTX GlobeNewsWire — January 09, 2026Access the Akari CEO Corner here
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your Rights - TLX — Neutral
TLX PRNewsWire — January 09, 2026NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Telix Pharmaceuticals Ltd. ("Telix Pharmaceuticals Ltd.
CVS Health to hold fourth quarter and full year 2025 earnings conference call — Neutral
CVS PRNewsWire — January 09, 2026WOONSOCKET, R.I., Jan. 9, 2026 /PRNewswire/ -- CVS Health® (NYSE: CVS) will hold a conference call with analysts and investors on Wednesday, February 11th, 2026, at 8:00 a.m.
Lost Money on Perrigo Company plc(PRGO)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky — Neutral
PRGO PRNewsWire — January 09, 2026NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Perrigo Company plc ("Perrigo Company plc" or the "Company") (NYSE: PRGO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Perrigo Company plc investors who were adversely affected by alleged securities fraud between February 27, 2023 and November 4, 2025.
Class Action Filed Against Primo Brands Corporation / Primo Water Corporation (PRMB) - January 12, 2026 Deadline to Join - Contact Levi & Korsinsky — Neutral
PRMB PRNewsWire — January 09, 2026NEW YORK, Jan. 9, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Primo Brands Corporation / Primo Water Corporation ("Primo Brands Corporation / Primo Water Corporation" or the "Company") (NYSE: PRMB) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Primo Brands Corporation / Primo Water Corporation investors who were adversely affected by alleged securities fraud between June 17, 2024 and November 6, 2025.